E-drug: Re: US compulsory licensing proposal for medicines (contd)
-------------------------------------------------------------------------
Joel Lexchin doesn't give credibility to the Tufts University Center for
the
Study of Drug Development. I put little stock in reports written by
professional economists. Perhaps a different, and, I think informative,
slant
on the current and foreseeable status of the financial health of the
research-based pharmaceutical industry is the plenary lecture that Dr Steve
Arlington gave at the 2001 annual meeting of the American Society for
Clinical
Pharmacogy & Therapeutics. His slides tell the story, very graphically and
colorfully. They can be found at the website of the ASCPT, which is
www.ascpt.com
At the home page look to the item in the lower left corner, which is
information from the 2001 Annual Meeting, and click on the highlighted item
for
Steve Arlington's presentation.
It's a 3 megabyte adobe pdf file, and you need the Adobe reader 4.0 or
higher
to read it. 3.0 won't work. If you have a slow internet connection it
will
take a long time to download.
Arlington is the chief pharmaceutical analyst for PriceWaterhouseCoopers in
London, and a very knowledgeable observer of the pharma industry. The
basic
orientation is total shareholder value, which historically has been very
high,
but appears to be starting to droop a bit, as his lecture points out.
John Urquhart, MD, FRCP(Edin)
Professor of Pharmacoepidemiology, Maastricht University, Maastricht, NL
Chief Scientist, AARDEX Ltd/APREX Corp, Zug CH & Union City, CA, USA
Professor of Biopharmaceutical Sciences, UCSF, San Francisco
home office: Palo Alto, CA 94301 USA
email: urquhart@ix.netcom.com
--
Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'.
Information and archive http://www.healthnet.org/programs/edrug.html
Mail administrative requests to `majordomo@usa.healthnet.org'.
For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.